Insight Molecular Diagnostics
IMDX
45 hedge funds and large institutions have $21.7M invested in Insight Molecular Diagnostics in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 3 reducing their positions, and 2 closing their positions.
858% more capital inflows, than outflows
Capital inflows: $1.63M | Capital outflows: $170K
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
400% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 3
22% more funds holding
Funds holding: 37 → 45 (+8)
0.8% more ownership
Funds ownership: 14.08% → 14.88% (+0.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.26M |
| 2 |
BlackRock
New York
|
+$97.1K |
| 3 |
State Street
Boston,
Massachusetts
|
+$89.6K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$58.5K |
| 5 |
Morgan Stanley
New York
|
+$34.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Family Management
New York
|
-$155K |
| 2 |
Legal & General Group
London,
United Kingdom
|
-$9.8K |
| 3 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
-$2K |
| 4 |
Bank of New York Mellon
New York
|
-$1.58K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.58K |
IMDX Hedge Fund Activity: Q4 2017 in Review
45 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q4 2017, worth a combined $21.7M — down 35% from $33.3M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new IMDX positions and 2 closed out — a net gain of 8 holders — while 15 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.26M. The largest seller was Family Management, exiting entirely with an estimated $155K sold.
- 45 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q4 2017, up from 37 in Q3 2017.
- Funds reported $21.7M of Insight Molecular Diagnostics stock for Q4 2017, down 35% quarter-over-quarter.
- 10 funds opened new Insight Molecular Diagnostics positions in Q4 2017 and 2 closed out, a net change of +8 holders.
- The largest Insight Molecular Diagnostics buyer in Q4 2017 was Vanguard Group, an estimated $1.26M added.
- The largest Insight Molecular Diagnostics seller in Q4 2017 was Family Management, an estimated $155K sold.
Based on aggregated 13F filings for Q4 2017.